story of the week
FDA Announces Approval, CMS Proposes Coverage of First Breakthrough-designated Test to Detect Extensive Number of Cancer Biomarkers
FDA approves test to detect mutations in 324 genes, two genomic signatures. Second to be approved with proposed coverage under FDA/CMS Parallel Review Program.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.